Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs Regeneron Pharmaceuticals Inc — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $25.31 (market cap $142.30B), while Regeneron Pharmaceuticals Inc trades at $663.15 (market cap $68.79B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 2.1× Regeneron Pharmaceuticals Inc's market cap, and Banco Bilbao Vizcaya Argentaria SA pays the higher dividend (4.2%). Which is the better fit depends on your goals.
| BBVA | REGN | |
|---|---|---|
Market Cap | $142.30B | $68.79B |
Sector | Financials | Health |
52-Week High | $26.14 | $812.27 |
52-Week Low | $14.73 | $542.52 |
Dividend Yield | 4.2% | 0.57% |
Enterprise Value | — | $62.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $25.39, down 1.17% on the day, with a bullish technical signal from moving averages and strong fundamental metrics including a 26.51% net income margin and 18.67% ROE. Recent earnings beat expectations in Q1 2026, and revenue has grown steadily from $28.2B in 2022 to $39.4B in 2025. Positive analyst sentiment is reflected in a 53.85% buy rating, though legal and regulatory risks from ongoing probes in Spain present headwinds.
The outlook for BBVA remains positive given robust profitability and analyst support, but investors should weigh the stock's attractive valuation against litigation risks and sector volatility. Upside potential exists if earnings continue to exceed forecasts, but legal developments could pressure the share price near-term.
Regeneron (REGN) trades at $663.09, down slightly by 0.22% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability, with a net income margin of 29.65% and consistent earnings beats in recent quarters. Recent positive news includes FDA and EMA acceptance of its cemdisiran application for gMG and selection for an FDA pilot program to accelerate manufacturing reviews, highlighting operational momentum.
The outlook remains positive given analyst consensus with a $764.50 price target and no sell ratings, though risks include regulatory hurdles and competitive pressures in biotech. Earnings growth and pipeline advancements are key catalysts, but investors should weigh high RSI levels suggesting potential near-term overbought conditions against strong fundamental performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
